TY - JOUR
T1 - Stem Cell Therapy in Single-Ventricle Physiology
T2 - Recent Progress and Future Directions
AU - Abdullah, Mohamed
AU - Kegel, Samantha
AU - Gunasekaran, Muthukumar
AU - Saha, Progyaparamita
AU - Fu, Xuebin
AU - Mishra, Rachana
AU - Sharma, Sudhish
AU - Sunjay Kaushal, Kaushal
N1 - Funding Information:
Funding: This work is supported by grants from the National Institute of Health to S. Kaushal (HL141922, HL139060, HL145644, HL118491-06A1) and M. Abdullah (T32 AR 007592). M. Gunasekaran (2018-MSCRFF-4326 & 2020-MSCRFD-5338) and R. Mishra (2018-MSCRFD-4329) were supported by the Maryland Stem Cell Research Foundation. S. Sharma (18CDA34110282) was supported by the American Heart Association Career Development Award.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/1
Y1 - 2021/1
N2 - Current surgical and medical treatment options for single ventricle physiology conditions remain palliative. On the long term, despite treatment, the systemic ventricle has a significant risk of developing failure. There are unmet needs to develop novel treatment modalities to help ameliorate the ventricular dysfunction. Advances in the field of stem cell therapy have been promising for the treatment of heart failure. Numerous stem cell populations have been identified. Preclinical studies in small and large animal models provide evidence for effectiveness of this treatment modality and reveal several mechanisms of action by which stem cells exert their effect. Many clinical trials have been designed to further investigate the therapeutic potential that stem cell therapy may hold for pediatric populations with single ventricle physiology. In this review, we discuss the stem cell types used in these populations, some preclinical studies, and the clinical trials of stem cell therapy in single ventricle patients.
AB - Current surgical and medical treatment options for single ventricle physiology conditions remain palliative. On the long term, despite treatment, the systemic ventricle has a significant risk of developing failure. There are unmet needs to develop novel treatment modalities to help ameliorate the ventricular dysfunction. Advances in the field of stem cell therapy have been promising for the treatment of heart failure. Numerous stem cell populations have been identified. Preclinical studies in small and large animal models provide evidence for effectiveness of this treatment modality and reveal several mechanisms of action by which stem cells exert their effect. Many clinical trials have been designed to further investigate the therapeutic potential that stem cell therapy may hold for pediatric populations with single ventricle physiology. In this review, we discuss the stem cell types used in these populations, some preclinical studies, and the clinical trials of stem cell therapy in single ventricle patients.
KW - Cavopulmonary shunt
KW - Fontan circulation
KW - Heart failure
KW - Right ventricle
KW - Single ventricle
KW - Stem cells
KW - Systemic ventricle
UR - http://www.scopus.com/inward/record.url?scp=85104131568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104131568&partnerID=8YFLogxK
U2 - 10.1053/j.pcsu.2021.03.003
DO - 10.1053/j.pcsu.2021.03.003
M3 - Review article
C2 - 34116785
AN - SCOPUS:85104131568
SN - 1092-9126
VL - 24
SP - 67
EP - 76
JO - Pediatric Cardiac Surgery Annual
JF - Pediatric Cardiac Surgery Annual
ER -